FAQ · Research guide
Retatrutide FAQ
Common questions on the trials, the doses and the weight loss numbers.
Every figure here comes straight from the published phase 2 and phase 3 (TRIUMPH) trials, the same numbers as the Retatrutide Phase 3 Research Guide.
01 / QUESTION
What is retatrutide?
Retatrutide is a once-weekly injectable research compound from Eli Lilly that acts on three receptors: GIP, GLP-1 and glucagon. It is not approved anywhere yet and is still investigational.
02 / QUESTION
How much weight did people lose in the phase 3 trials?
At 80 weeks in TRIUMPH-1 (obesity, no diabetes): 19.0% at 4 mg, 25.9% at 9 mg, 28.3% at 12 mg. In TRIUMPH-2 (obesity + type 2 diabetes): 12.7% at 4 mg, 19.1% at 9 mg, 20.8% at 12 mg. Placebo lost 4.0%.
In TRIUMPH-1, 45.3% of the 12 mg group lost 30% or more of their body weight.
03 / QUESTION
What are the TRIUMPH trials?
TRIUMPH is the phase 3 program. TRIUMPH-1 put 2,339 people with obesity but no diabetes on 80 weeks and the 12 mg group lost 28.3%. TRIUMPH-2 put 1,152 people with obesity and type 2 diabetes on 80 weeks and 12 mg lost 20.8%. TRIUMPH-3 covered 1,949 people with severe obesity plus heart disease (22.6% at 12 mg over 80 weeks), and TRIUMPH-4 covered 445 people with obesity and knee osteoarthritis (28.7% at 12 mg over 68 weeks).
04 / QUESTION
What did the earlier phase 2 trial show?
338 people over 48 weeks. The 12 mg group lost 24.2% of body weight, already ahead of what TRIUMPH-1 later confirmed at week 48 (24.2%).
05 / QUESTION
How fast does the weight come off?
On 12 mg: 17.5% at week 24, 24.2% at week 48, 28.3% at week 80. Weeks 24 and 48 are from the phase 2 trial, week 80 from TRIUMPH-1. The curve was still dropping at week 48 with no plateau; judge it at months, not weeks, because the first 16 weeks are mostly titration.
06 / QUESTION
How is retatrutide dosed in the trials?
In the phase 3 TRIUMPH trials, every retatrutide arm started at 2 mg once weekly and stepped up every four weeks until it reached its target dose, on this schedule: 2 mg in weeks 1-4, 4 mg in weeks 5-8, 6 mg in weeks 9-12, 9 mg in weeks 13-16 and, for the 12 mg arm, 12 mg from week 17. The phase 2 obesity trial of retatrutide (Jastreboff, NEJM 2023) used escalation steps different from those of the phase 3 TRIUMPH trials: its 12 mg arm stepped through 2, 4 and 8 mg before reaching 12 mg.
2 mg was only ever a starting step. No trial kept anyone on 2 mg, so there is no 2 mg result.
07 / QUESTION
What are the most common side effects?
GI effects (nausea, vomiting, diarrhea, constipation) were the most common, mostly mild to moderate, and concentrated during dose increases, which is why the four-week holds exist.
11-18% quit the 12 mg dose over side effects (11.3% in TRIUMPH-1, 18.2% in TRIUMPH-4; placebo was 4-5%). Lower doses dropped out less: 4.1% at 4 mg in TRIUMPH-1, below placebo.
08 / QUESTION
What is dysesthesia?
An altered skin sensation unique to this drug class. At 12 mg it affected 7-21% of participants: 7.3% in TRIUMPH-2 and 20.9% in TRIUMPH-4.
09 / QUESTION
Does retatrutide raise heart rate?
Phase 2 recorded a peak resting heart rate rise of +6.7 beats per minute at 12 mg, highest around week 24 and easing after. Approved drugs in the same class carry label warnings for pancreatitis, gallbladder disease and thyroid C-cell tumors (seen in rodents).
10 / QUESTION
Is retatrutide approved?
No. It is not approved in any country as of now. The realistic timeline: Lilly files the BLA with the FDA in Q1 2027, standard review adds 10-12 months, making late 2027 the earliest realistic approval.
11 / QUESTION
How do the retatrutide trial dose steps translate into reconstitution arithmetic?
In a laboratory, 10 mg of peptide dissolved in 1 mL of bacteriostatic water gives a 10 mg per mL solution, and on a U-100 syringe, 10 units (0.1 mL) of that solution contain 1 mg of peptide, so the 2, 4, 6 and 9 mg steps of the phase 3 TRIUMPH dose schedule for retatrutide correspond to 20, 40, 60 and 90 units. At 10 mg per mL, the 12 mg step of the TRIUMPH schedule for retatrutide corresponds to 120 units (1.2 mL), which is more than a 1 mL U-100 syringe holds and more than a vial of 10 mg in 1 mL contains; at 15 mg per mL (30 mg of peptide in 2 mL), 12 mg corresponds to 80 units. BodyHackGuide's reconstitution calculator takes a vial size, a water volume and an amount and returns the mg per mL concentration and the number of syringe units that contain that amount. Converting the TRIUMPH dose steps for retatrutide into syringe units is research arithmetic for laboratory use, not a dosing instruction.
12 / QUESTION
What did the retatrutide trials measure?
The phase 2 obesity trial of retatrutide (Jastreboff, NEJM 2023) and the phase 3 TRIUMPH trials measured body weight, waist circumference, heart rate, A1C, fasting glucose and lipids, each at baseline and at scheduled visits.
MORE
Keep reading
For research and educational purposes only. Retatrutide is investigational and not approved for human use in any jurisdiction. Not medical advice.